Gene and cell therapy for life-threatening cardiac arrhythmias: Will they replace drugs, surgery, and devices?

Dialogues in Cardiovascular Medicine

Volumn 14, Issue 1, 2009, Pages 44-51

  Rosen, Michael R ^a   Danilo Jr , Peter ^a   Robinson, Richard B ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Atrial fibrillation; Myocardial infarction; Reentry; Stem cells; Ventricular fibrillation; Ventricular tachycardia; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNEXIN 43; CYCLIC NUCLEOTIDE GATED CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; GAP JUNCTION PROTEIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; POTASSIUM CHANNEL HERG; ROTIGAPEPTIDE; SMALL INTERFERING RNA; SODIUM CHANNEL; SOTALOL; UNCLASSIFIED DRUG;

ARTICLE; CATHETER ABLATION; DEFIBRILLATION; DRUG TARGETING; ELECTROPORATION; EMBRYONIC STEM CELL; GENE OVEREXPRESSION; GENE THERAPY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART SURGERY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MEDICAL RESEARCH; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT CARE; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SINUS NODE; STEM CELL TRANSPLANTATION; SUDDEN DEATH; SURGICAL EQUIPMENT; SURVIVAL RATE; TISSUE REGENERATION; UNITED STATES; VIRAL GENE DELIVERY SYSTEM;

EID: 65549163928     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Myerburg RJ, Feigal DW Jr, Lindsay BD. Life-threatening malfunction of implantable cardiac devices. N Engl J Med. 2006;354:2309-2311.
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.
3. Wit AL, lanse MJ. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation. 1992:85:132-1142.
4. Mines GR. On circulating excitattons ni heart muscles and their possible relation to tachycardia and fibrillation. Trans R Soc Can. 1914;IV:43-52.
5. Schmitt FO, Erlanger J. Directional differences in the conduction of the impulse through heart muscle and their possible relations to extrasystolic and fibrillary contractions. Am J Physiol. 1928;87:326-347.
6. Allessie MA, Bonke FIM, Schopman FJG. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: A new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res. 1977;41:9-18.
7. Fuster V, Ryden LE, Cannorn DS, et al. American College of Cardiology. American Heart Association Task Force on Practice Guidelines. European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2006;48:854-906.
8. Spooner PM, Rosen MR. Perspectives on arrhythmogenesis, antiarrhythmic strategies and sudden cardiac death. In: Spoon er PM, Rosen MR, eds. Foundations of Cardiac Arrhythmias. New York, NY; Marcel Dekker Inc; 2000: 1-20.
9. Ducharme A, Swedberg K, Pfeffer MA, et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006; 152:86-92.
10. Members of the Sicilian Gambit. Antiarrhythmic Therapy: A Pathophysiologic Approach. Armonk, NY: Futura Publishing Co; 1994.
11. Rosen M. Biological pacemaking: In our lifetime? Heart Rhythm. 2005;2:418-428.
12. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nature Med. 2006;12:1256-1258.
13. Bauer A, McDonald AD, Nasir K, et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004; 110:3115-3120.
14. Murata M, Cingolani E, McDonald AD, Donahue JK, Marban E. Creation of a genetic calcium channel blocker by targeted gem gene transftr in the heart. Circ Res. 2004;95:398-405.
15. Bunch TJ, Mahapatra S, Bruce GK, et al. Impact of transforming growth factor-βl on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation. 2006;113:2485-2494.
16. Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nature Biotochnol. 2004;22:1282-1289.
17. Potapova I, Plotnikov A, Lu Z, et al. Human mesenchymal stem cell as a gene delivery system to create cardiac pacemakers. Circ Res. 2004;94:841-959.
18. Plotnikov AP, Shlapakova I, Szabolcs MI, et al. Xerrografted adult human mesenchymal stem cells provide. a platform for sustained biological pacemaker fiawtion in canine heart. Circulation. 2007;116:706-713.
19. Cho HC, Kashiwakura Y, Marban E. Creation of a biological pacemaker by cell fusion. Circ Res. 2007;100:1112-1115.
20. Choi YH, Stamm C, Hammer PE, et al. Cardiac conduction through engineered tissue. Am J Pathol. 2006;169:72-85.
21. Lehnart SE, Donahue JK. Coronary perfusion cocktails for in vivo gene transfer. Methods Mol Biol. 2003;219:213-218.
22. Roth DM, Lai NC, Gao MH, et al. Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice. Am j Physiol Heart Circ Physiol. 2004;287:H172-H177.
23. Zimmett JM, Hare JM. Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res Cordiol. 2005;100:471-481.
24. Perlstein I, Burton DY, Ryan K, et al. Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions. Hum Gene Ther. 2005;16:906-910.
25. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657-2665.
26. Lau DH, Clausen C, Sosunov EA, et al. Epicardial border zone overexpression of skeletal muscle sodium channel, SkM1, normalizes activation, preserves conduction and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation. 2009;119:19-27.
27. Betsuyaku T, Nnebe NS, Sundset R, Patibandla S, Krueger CM, Yamada KA. Overexpression ofcardiac connexin45 increases susceptibility to ventricular tachyarrhythmias in vivo. Am J Physiol Heart Circ Physiol. 2006;290:H163-H171.
28. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354:2677-2688.
29. Peters NS, Coromilas J, Severs NJ, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachyeardia. Circulation. 1997;95:988-996.
30. Dhein S, Larsen BD, Petersen JS, Mohr FW. Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Commun Adhes. 2003;10:371-378.
31. k1) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol. 2001;533:697-710.
32. Hua F, Johns DC, Gilmore RF Jr. Suppression ofelectrical alternans by overexpression of HERG in canine ventricular myocytes. Am J Physiol Heart Circ Physiol. 2004;286:H2342-H2352.